Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.52 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.52 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.44 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.42 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.74 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.74 |
| ▸ | PNMT | P11086 | 5/20 | 0.52 |
| ▸ | CD44 | P16070 | 1/20 | 0.52 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15238605 | 1.00 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL587887 | 0.98 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL29850369 | 0.98 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL29759853 | 0.92 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL785959 | 0.92 | CHRNB2 (0.74) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL2565015 | 0.90 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL30183351 | 0.90 | CHRNB2 (0.77) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL19194504 | 0.86 | SIGMAR1 (0.61) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| SCHEMBL19200207 | 0.85 | CHRNB2 (1.00) | CHRNB2CHRNA4PNMTSIGMAR1CD44 | |
| Hydrochloric Acid SCHEMBL9317481 | 0.83 | CHRNB2 (0.54) | CHRNB2CHRNA4PNMTSIGMAR1CD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4129402-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115298173-A | Hydroxypyrrolidine derivatives and medical use thereof | 田边三菱制药株式会社 | 2022-11-04 | — | — | CN | disclosed |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-9820989-B2 | Method of treating conditions with kinase inhibitors | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2825537-B1 | DIHYDROPYRIDOPYRIMIDINE AND DIHYDRONAPHTHYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS OF ESPECIALLY VEGF AND PDGF | ALLERGAN INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9388176-B2 | Method of treating conditiions with kinase inhibitors | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2825537-A1 | DIHYDROPYRIDOPYRIMIDINE AND DIHYDRONAPHTHYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS OF ESPECIALLY VEGF AND PDGF | ALLERGAN, INC. (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825166-A1 | METHOD OF TREATING OPHTHALMIC CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8889870-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| WO-2013138393-A1 | METHOD OF TREATING OPHTHALMIC CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138396-A1 | DIHYDROPYRIDOPYRIMIDINE AND DIHYDRONAPHTHYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS OF ESPECIALLY VEGF AND PDGF | ALLERGAN, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130237538-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2009001128-A1 | 1,2-CYCL0HEXANE DICARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | SIGMAR1 2849/4885MAOB 888/4885ADRA2A 2021/4885 |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | VHL, MDM2, NEDD4 | SIGMAR1 2478/4885MAOB 4508/4885ADRA2A 3494/4885 |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | SIGMAR1 2849/4885MAOB 888/4885ADRA2A 2021/4885 |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | CDK5, MAP3K1, ALDH1A2 | SIGMAR1 3089/4885MAOB 889/4885ADRA2A 2380/4885 |
| US-20130237538-A1 | KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K2 | SIGMAR1 3695/4885MAOB 1653/4885ADRA2A 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.